Objective The discontinuation of dual antiplatelet therapy (DAPT) increases the risk of stent thrombosis after coronary stenting. Some patients must discontinue DAPT due to gastrointestinal (GI) tract disease; however, the type of examination that is most useful for detecting GI tract diseases has not been fully evaluated. The purpose of this study was to clarify whether the immunochemical fecal occult blood test (iFOBT) can be used to predict GI tract disease-related DAPT discontinuation following stent implantation in patients with coronary artery disease. Methods A total of 181 consecutive DAPT-naïve patients who underwent coronary stenting were divided into two groups according to the results of iFOBTs: a positive iFOBT group (n=32) and a negative iFOBT group (n=149). During the 12-month follow-up period, the DAPT discontinuation rate was lower in the negative iFOBT group than in the positive iFOBT group (3.4 vs. 18.8%, p=0.005). Kaplan-Meier event-free curves showed that the DAPT discontinuation rate in the negative iFOBT group was lower than that observed in the positive iFOBT group (log-rank test: p=0.001). Logistic and Cox regression analyses showed that a positive iFOBT result was the strongest predictor of the risk of DAPT discontinuation after coronary stenting. Conclusion A positive iFOBT result is associated with DAPT discontinuation following coronary stenting.
Introduction
Stent thrombosis is a serious complication that can be caused by the premature discontinuation of dual antiplatelet therapy (DAPT) (1) (2) (3) in patients who have undergone the placement of a coronary stent for coronary artery disease (CAD). According to the American College of Cardiology/ American Heart Association (4) and the European Society of Cardiology guidelines (5), DAPT should be administered for at least 12 months after stent (e.g., a bare metal stent [BMS] or drug-eluting stent [DES] ) implantation in order to decrease the risk of stent thrombosis in patients with high-risk diseases, such as acute coronary syndrome (ACS). However, the rate of DAPT discontinuation among patients treated with coronary stenting is relatively high. A previous study showed that 8 .8% of CAD patients discontinued one or both antiplatelet drugs within the first 12 months after DES implantation (6) . Furthermore, we previously showed that 11.2% of ACS patients discontinued DAPT within 12 months after percutaneous coronary intervention (PCI) (7) . A primary reason for the discontinuation of DAPT is bleeding in the gastrointestinal (GI) tract (8, 9) . A recent study revealed that GI tract bleeding episodes are frequently observed in patients with DAPT regardless of the administration of proton pump inhibitors or H2 blockers (10) . Based on these results, screening for GI tract diseases could have a clinical advantage in terms of predicting DAPT discontinuation. The immunochemical fecal occult blood test (iFOBT) is a well-established and effective screening examination for detecting GI tract diseases. However, the benefits of iFOBTs for predicting DAPT discontinuation within 12 months after PCI have not been evaluated.
The purpose of this study was to clarify whether the iFOBT can be used to predict GI disease-related DAPT discontinuation following stent implantation in patients with CAD.
Materials and Methods

Subjects
From November 2004 to March 2011, 374 patients with untreated CAD who were admitted to our institution for PCI were consecutively recruited. The study was conducted according to the principles of the Declaration of Helsinki, and all of the patients provided their written informed consent prior to their inclusion in the trial. The following data were recorded at baseline: clinical characteristics (e.g., age, sex, BMI, blood pressure, history of ACS and type of stent implanted), cardiac risk factors (e.g., hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease (CKD) and smoking status), medications (e.g., renin-angiotensinaldosterone blockers, beta blockers, statins, Ca 2+ antagonists, proton pump inhibitors, H2 blockers and anticoagulant therapy) and laboratory data, including the red blood cell count, hemoglobin level, hematocrit level, mean corpuscular volume, mean corpuscular hemoglobin concentration, blood urea nitrogen (BUN)/creatinine ratio, estimated glomerular filtration rate (eGFR) and high-sensitivity C-reactive protein (hs-CRP) level.
The eGFR was calculated using the Modification of Diet in Renal Disease equation (11) For the iFOBT, an automated semi-quantitative OCSensor (Eiken Chemical Co., Tokyo, Japan) was used. Fecal samples, preserved in liquid buffer in a plastic container, were processed using an OC-Micro instrument (Eiken Chemical Co.). In accordance with the manufacturer's instructions, the threshold for positivity was 100 ng mL -1 . Each patient underwent an iFOBT on two consecutive days. A positive iFOBT result was recorded if a positive result was obtained at least once. Screening using the iFOBT was performed within one month before or after admission in patients undergoing elective PCI and within one month after admission in ACS patients experiencing PCI. If a positive result was obtained, the patient underwent endoscopy in the upper and lower portions of the GI tract to determine the presence of an ulcer or tumor.
Coronary intervention and antiplatelet therapy
PCI was performed in all enrolled CAD patients on admission, with the placement of a BMS or DES at the discretion of the interventional cardiologist. A standard dose of aspirin (81 or 100 mg daily) was given to all patients. Patients who received a BMS or DES were also given a thienopyridine antiplatelet agent (200 mg of ticlopidine daily or a 300-mg loading dose of clopidogrel followed by 75 mg daily). In all cases of PCI, the enrolled patients continued antiplatelet therapy during the 12-month follow-up period, except for those who experienced serious bleeding events.
Follow-up and definition of DAPT discontinuation
DAPT discontinuation was defined as the cessation of DAPT due to major or moderate GI tract bleeding events and non-cardiac surgery-caused GI tract disease. Major and moderate bleeding events were defined as a composite of types 5 and 3 based on the Bleeding Academic Research Consortium criteria, as previously described (12) . In the present study, patients with drug noncompliance were excluded from the analysis of DAPT discontinuation. All enrolled patients who underwent PCI received drug administration guidance to prevent drug noncompliance events. Follow-up data were obtained from medical records and personal interviews and were available for >95% of the patients.
Statistical analysis
Comparisons were made using chi-square statistics, unpaired Student's t-tests or an analysis of variance. Multivariate analyses were performed using a logistic regression analysis and Cox proportional hazards model. The candidate variables entered into the model included background details (e.g., age, sex and BMI), the presence or absence of ACS, the presence or absence of anemia, the BUN/creatinine ratio, the hs-CRP level and positive iFOBT results. A p value of <0.05 was considered to indicate statistical significance. Event rate curves were drawn using the Kaplan-Meier method, and the log-rank test was used to compare event rates between the two groups. All analyses were performed using the Statistical Package for the Social Sciences ver. 19.0 (SPSS Inc., Chicago, USA).
Results
Follow-up and incidence of DAPT discontinuation
During the 12-month follow-up period, 374 consecutive CAD patients who were treated with PCI therapy were enrolled and analyzed retrospectively. A total of 188 patients who did not undergo an iFOBT were excluded from this study. Of the 186 patients who underwent an iFOBT, four who were lost to follow-up and one who underwent coronary artery bypass grafting after coronary intervention were excluded in the final analysis. Ultimately, 181 CAD patients were assessed for eligibility in the present study.
The discontinuation of DAPT was observed in 11 (6.1%) of the 181 patients. DAPT discontinuation occurred in seven patients due to GI tract bleeding and in four patients due to surgery for GI cancer. The flowchart in Fig. 1 details the study population and incidence of DAPT discontinuation during the 12-month follow-up period. The rate of GI tract disease-related DAPT discontinuation was lower in the negative iFOBT group than in the positive iFOBT group (3.4 vs. 18.8%, p=0.005). The positive and negative predictive values of the iFOBT for the discontinuation of DAPT due to GI tract disease were 18.8% and 96.6%, respectively.
Patient characteristics
The mean (± standard deviation) age of the patients was 68.4±9.9 years (range, 36-88 years). Of the 181 patients, 139 (76.8%) were men, 58 (32.0%) had ACS, 148 (81.8%) had hypertension, 142 (78.5%) had dyslipidemia, 84 (46.4%) had diabetes mellitus and 52 (28.7%) had CKD. A total of 94 (46.4%) patients were current smokers or had a history of smoking.
No significant differences were noted in the patients' baseline characteristics, including age, sex, BMI, history of ACS, type of stent implanted, blood pressure and the prevalence of hypertension, dyslipidemia, diabetes mellitus, CKD and smoking, between the positive and negative iFOBT groups. The medications used after PCI, including proton pump inhibitors, H2 blockers, Ca 2+ antagonists, reninangiotensin-aldosterone blockers, beta blockers, aldosterone antagonists, statins, anticoagulant drugs and antiplatelet drugs (e.g., ticlopidine and clopidogrel), also did not differ between the positive and negative iFOBT groups (Table 1) . Sirolimus-eluting stents were implanted in 35 patients, paclitaxel-eluting stents were implanted in 22 patients, everolimus-eluting stents were implanted in 17 patients and zotarolimus-eluting stents were implanted in five patients.
The hemoglobin levels, hematocrit levels and mean corpuscular hemoglobin concentrations were lower in the patients with a positive iFOBT result than in those with a negative iFOBT result. The other laboratory data did not differ between the two groups ( Table 1) .
Univariate and multivariate analyses of potential predictors of DAPT continuation
The data obtained from a multivariate analysis of potential predictors of DAPT discontinuation are summarized in Table 2 . Our results indicate that a positive iFOBT result, the hs-CRP level, a history of ACS, the BUN/creatinine ratio, the hemoglobin level and the hematocrit level were significantly associated with DAPT discontinuation. In a logistic regression analysis, a positive iFOBT result, the hs-CRP level, a history of ACS, the BUN/creatinine ratio, the hemoglobin level and the hematocrit level were significantly associated with DAPT discontinuation. A Cox regression analysis showed that a positive iFOBT result was the strongest predictor of DAPT discontinuation (Table 3) .
Comparison of DAPT continuation between the patients with a positive and negative iFOBT result Fig. 2 shows Kaplan-Meier survival curves for the continuation of DAPT. During the 12-month follow-up period, the rate of DAPT continuation was higher in the negative iFOBT group than in the positive iFOBT group (p=0.001). The rate of DAPT discontinuation was >15% in the positive iFOBT group.
Discussion
This study demonstrates the utility of the iFOBT for predicting DAPT discontinuation due to GI tract disease following stent implantation. The major findings of the present study are as follows. First, DAPT discontinuation, which was related to GI tract bleeding, occurred in 6.1% of the en- rolled patients (3.9% of the patients experienced major bleeding events related to GI tract disease; 2.2% of the patients experienced bleeding due to surgery for GI tract cancer). Second, the hemoglobin levels, hematocrit levels and mean corpuscular hemoglobin concentrations were lower in the positive iFOBT group than in the negative iFOBT group. Third, the Kaplan-Meier survival curves showed that the rate of DAPT discontinuation in the positive iFOBT group was higher than in the negative iFOBT group during the 12-month follow-up period. Fourth, higher serum levels of hs-CRP were associated with DAPT discontinuation in the CAD patients treated with coronary stenting. Finally, a multivariable analysis showed that a positive iFOBT result was the strongest predictor of the avoidance of DAPT continuation. Several studies have shown that the occurrence of GI tract disease (e.g., GI bleeding and malignant disease) is a common reason for DAPT discontinuation in CAD patients treated with PCI. The ACDC study, which investigated the discontinuation of antiplatelet therapy after DES implantation, showed that GI tract bleeding events occurred in 1.23% of CAD patients, while colon surgery occurred in 0.12% of CAD patients over a 12-month period. Additionally, that study found that GI tract disease was the most common reason for DAPT discontinuation (9) . The CHARISMA study, a double-blind, placebo-controlled, randomized trial comparing clopidogrel (75 mg per day) plus low-dose aspirin (75-162 mg per day) with a placebo plus low-dose aspirin showed that major and moderate bleeding events occurred in 3.1% of CAD patients during 12 months of follow-up and that more than half of those who discontinued antiplatelet therapy did so due to GI tract bleeding (8) . In the present study, major bleeding events due to GI tract disease were observed in 3.9% of the CAD patients, while surgery for GI tract cancer occurred in 2.2% of the enrolled patients. The prevalence of CAD associated with DAPT discontinuation related to GI tract disease in this study was similar to that observed in previous studies.
In terms of the baseline characteristics, the hemoglobin levels, hematocrit levels and mean corpuscular hemoglobin concentrations were lower in the positive iFOBT group than in the negative iFOBT group. These results demonstrate that GI tract bleeding or cancer may lead to anemia in patients with a positive iFOBT result. A positive iFOBT result suggests the potential for GI tract disease, which can cause DAPT discontinuation after coronary stenting.
Bleeding events in the GI tract are common in CAD patients receiving DAPT despite the administration of proton pump inhibitors (10) . Previous studies have shown that the iFOBT result is an effective diagnostic marker for advanced colorectal neoplasms in patients taking low-dose aspirin compared to those not taking aspirin (13) . The prevalence of advanced adenoma is higher in CAD patients than in normal subjects (14) . Therefore, iFOBT results may be more valuable in CAD patients receiving DAPT than in healthy subjects. According to these data, screening for GI tract disease has the potential to predict DAPT discontinuation. Eventfree survival curves showed that the percentage of patients with DAPT discontinuation in the negative iFOBT group was lower than that observed in the positive iFOBT group, indicating that iFOBT results are suitable not only for screening for GI tract disease but also for use as predictors of DAPT discontinuation.
Screening for GI tract diseases using iFOBTs may produce false-positive results. Indeed, more than 80% of the CAD patients with a positive iFOBT result continued to receive DAPT during the follow-up period. However, the percentage of patients who discontinued DAPT due to GI tract disease in the positive iFOBT group was higher than that observed in the negative iFOBT group. Additionally, the negative predictive value was high (96.6%) in this study. These data indicate that cardiologists can establish the treatment plan before PCI based on the results of iFOBTs. This is useful because ACS patients often require urgent transfer from the emergency department to cardiac catheterization; thus, interventional cardiologists may not have sufficient time to perform upper and lower GI endoscopy.
Our logistic and Cox regression analyses showed that a positive iFOBT result was the strongest predictor of the discontinuation of DAPT. According to these data, if CAD patients have a positive iFOBT result before undergoing elective coronary stenting, a detailed examination for potential GI tract disease should be conducted in order to prevent the inadequate use of DAPT. Interestingly, our multivariate analysis showed that the level of hs-CRP was associated with the discontinuation of DAPT. Serum hs-CRP can affect the presence of GI tract disease-related tissue inflammation and damage, leading to the discontinuation of DAPT. Obtaining iFOBT results and measuring the hs-CRP level and anemia-related parameters may facilitate the diagnosis of GI tract disease.
Although several studies have shown that treatment with three or six months of DAPT is not inferior to standard DAPT therapy (15) (16) (17) , the optimal duration of DAPT following implantation of a BMS or DES remains undetermined. It is commonly accepted that DAPT therapy should be administered for at least 12 months after DES implantation, and that the optimal duration of DAPT for DES implantation is relatively long. Considering this background, our study shows that obtaining iFOBT results and measuring the hs-CRP level and anemia-related parameters may be useful for selecting the type of coronary stenting and avoiding the inadequate use of DAPT.
The present study has several limitations. First, the patients were enrolled at a single center. Second, in some patients, it was difficult to obtain the iFOBT results prior to performing coronary intervention. Improved examination procedures (e.g., the use of a mass survey or rectal examinations) that include iFOBTs should be established. Third, the optimal time for conducting iFOBTs before coronary stenting should be determined. Fourth, the diagnostic accuracy for detecting upper GI tract disease could be increased by the use of a combination of standard guaiac fecal occult blood tests and iFOBTs. However, in the usual clinical setting, it is difficult to perform iFOBTs and guaiac fecal occult blood tests simultaneously. Therefore, we assessed the presence of fecal occult blood using iFOBTs only. Finally, the results of the present study show a lack of predictive value for DAPT discontinuation related to non-GI tract diseases. Future prospective studies with large cohorts are needed to confirm the utility of the iFOBT for predicting DAPT discontinuation following coronary stenting.
In conclusion, a positive iFOBT result may be used to predict DAPT discontinuation in patients treated with coronary stenting. The iFOBT is useful for determining the optimal therapeutic strategy for treating CAD patients with PCI.
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